| HOME >> MEDICINE >> TECHNOLOGY |
NEW YORK, May 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The CMO Market Outlook to 2017
http://www.reportlinker.com/p0788285/The-CMO-Market-Outlook-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
This report examines the markets for contract manufacturing of finished dose forms and clinical quantity pharmaceuticals. The report forecasts CMO markets for the US, Western Europe, Eastern Europe, China, India, Other Asia, Latin America and the rest of the world to 2017. Drivers and restraints for each regional market as well as the global market are also examined.Develop contract manufacturing strategies based on regional forecast performance and key industry trends.Analyze the strengths and weaknesses of global players in the CMO market.Evaluate the future outlook of clinical quantity manufacturing as against finished dose supply.Assess the effects of CROs and big pharma drugmakers on the CMO market.Forecast CMO market sizes by region to 2017.In 2011, total global spending on outsourced drug manufacturing reached $31.9bn, having expanded at a double-digit pace over the past two decades. Over the next five years, the CMO industry will continue to record strong gains, with total revenues rising by 12.0% per year, on average.In 2011, the US and Western Europe accounted for a combined $23.3bn in CMO revenues from services performed in these regions, representing 73% of total global CMO fees of $31.9bn. However, China, India, Eastern Europe, Latin America, and Other Asia regions will outpace the traditional manufacturing centres of the US and Western Europe.In 2012 and 2013, drug manufacturers will be extremely cautious about investments in new technologies, equipment or facilities, preferring to outsource to established experts rather than incur heavy capital costs of building, expanding or upgrading their own internal capabilities, which will stimulate contract manufacturing.What factors are underpinning continued growth of the CMO market?Which regions will experience the greatest growth of CMO activity and how can sponsors optimize their work with CMOs in these areas?Between China and India, which has the greater potential for contract manufacturing to 2017?What are the leading players in each global region, and what are their recent activities?What is the potential of the Latin American and Eastern European CMO markets?
EXECUTIVE SUMMARY
•The shifting drug manufacturing landscape
•The continued growth of contract manufacturing
•Continued demand in the established regions
•Strong growth in the emerging regions
•Leading global CMOs
•The future of contract manufacturing
The shifting drug manufacturing landscape
•Summary
•Introduction
•Rising pressures on drug makers
- Blockbuster patent expirations and genericization
- Decreasing drug approvals
- Drug pricing pressures
- Excess manufacturing capacity
•Technology shifts
- Biotechnology
•Conclusion
The continued growth of contract manufacturing
•Summary
•Contract manufacturing organizations
- The role of CMOs
- Services offered by CMOs
•CMO usage, 2012–2017
- Global CMO forecasts by segment
- Global CMO forecasts by world region
•Drivers of rising CMO usage
- Cost savings
- Risk reduction
- Shifting manufacturing requirements
- Lead time savings
- Access to expertise
- Expansion of overseas CMOs
- Entrance of Big Pharma into contract manufacturing
- Vertical integration with CROs
- Emergence of specialty CMO players
- Risk sharing programs
•Restraints inhibiting greater CMO usage
- Pharma industry consolidation
- Lack of specialized manufacturing capacity
- Manufacturing budget reductions
- Heightened regulatory scrutiny
- CMO personnel shortages
- CMO alternatives
•Conclusion
Continued demand in the established regions
•Summary
•Introduction
•The US CMO market
- Overview
- US CMO usage by segment, 2011–2017
•The Western European CRO market
- Overview
- Western European CMO usage by segment, 2011–2017
•Conclusion
Strong growth in the emerging regions
•Summary
•Introduction
•The Eastern European CMO market
- Overview
•The Chinese CMO market
- Overview
- Chinese CMO usage by segment, 2011–2017
•The Indian CMO market
- Overview
- Indian CMO usage by segment, 2011–2017
•The Asian CMO market, exclusive of China and India
- Overview
- Other Asian CMO usage by segment, 2011–2017
•The Latin American CRO market
- Overview
- Latin American CMO usage by segment, 2011–2017
•Conclusion The emerging global markets for pharmaceutical contract manufacturing are growing quickly, fueled by sponsors' desire to reduce costs while improving manufacturing efficiencies. Each region, however, is subject to varying drivers and restraints based upon its own economy, demographics, legal and regulatory system/s, infrastructure, patent laws and other issues. While India and China are known for their high growth, other regions including Eastern Europe, Other Asian countries and Latin America also offer significant opportunities for both sponsors and third party organizations.
Leading global CMOs
•Summary
•Introduction
•Leading Players
- Aenova
- Boehringer Ingelheim
- Catalent Pharma Solutions
- Dr. Reddy's
- DSM
- Fareva
- Haupt
- Jubilant Organosys
- Lonza
- Patheon
- Piramal
- Tianjin Pharmaceutical
•Conclusion
The future of contract manufacturing
•Summary
•Introduction
•The drug manufacturing landscape in the US and EU
- Near term: 2012–2013
- Long term: 2014–2017
•Manufacturing outsourcing trends
- Near term: 2012–2013
- Long term: 2014–2017
•Conclusion
Appendix
•Scope
•Methodology
- Primary research
- Secondary research
•Glossary/Abbreviations
•Bibliography/References
FIGURES
•Figure: Usage of clinical and final dosage CMO services by type of drug maker
•Figure: Global CMO market by segment ($bn), 2012–17
•Figure: CMO market by region ($bn)
•Figure: CMO fees in the established regions ($bn), 2011–17
•Figure: US CMO fees by segment ($bn), 2011–17
•Figure: US CMO market players by market share, 2011
•Figure: Western European CMO fees by segment ($bn), 2011–17
•Figure: Western European CMO market players by market share, 2011
•Figure: Eastern European CMO fees by segment ($bn), 2011–17
•Figure: Eastern European CMO market players by market share, 2011
•Figure: Chinese CMO fees by segment ($bn), 2011–17
•Figure: Chinese CMO market players by market share, 2011
•Figure: Indian CMO fees by segment ($bn), 2011–17
•Figure: Indian CMO market players by market share, 2011
•Figure: Other Asian CMO fees by segment ($bn), 2011–17
•Figure: Leading Other Asian CMO market players, 2011
•Figure: Latin American CMO fees by segment ($bn), 2011–17
•Figure: Leading Latin American CMO market players, 2011
•Figure: Forces driving and restraining CMO growth in the near and long term
To order this report:
Drug and Medication Industry: The CMO Market Outlook to 2017
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |
Related medicine technology :
1. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
2. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
3. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
4. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
5. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
6. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
7. Ophthalmic Drugs: World Market Prospects 2012-2022
8. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |